

## **ADVANCED TRAINEE PROGRAM**

Saturday 30 & Sunday 31 July 2022

@ The Langham Hotel, Melbourne

### **SATURDAY 30TH JULY**

### **SESSION 1**

TIME	HAEMATOLOGY TRAINEES	TIME	MEDICAL ONCOLOGY TRAINEES	
	Chair:	10:20-12:30am	Chair: Dr Cameron McLaren, PCPA Board member	
10:30-12:30am	Prof. H. Miles Prince AM Epworth HealthCare	10:25-10:45am	'Equity of access – the new (philanthropic) frontier' Hayley Tamborini, Arrotex Pharmaceuticals	
10:40-11:30am	New agents in Myeloma Prof Hang Quach, St. Vincent's Hospital		Kirsten Pilatti, Breast Cancer Network Australia	
		10:45-11:45am	Update in adjuvant treatment of melanoma Dr Benjamin Brady, Cabrini Health	
11:30-12:30pm	New agents in CLL Prof Constantine Tam, The Alfred Hospital	11:45-12:30pm	Metastatic Breast Cancer: beyond the CDK4/6i's Dr Richard De Boer, Peter MaCallum Cancer Centre	
12:30-1:30pm	Lunch			

### **SESSION 2**

TIME	COMBINED SESSIONS	
1:30-1:40pm	Official Healthcare Address –The Hon Ged Kearney MP. Assistant Minister for Health and Aged Care	
1:40-1:55pm	Open digital ecosystems and the impact on cancer care, Nick Chapman, Roche Products	
1:55-2:35pm	Voluntary Assisted Dying in Victoria – three years later Dr Cameron McLaren, PCPA Board member	
2:35-3:15pm	The PCPA Business Academy Steven Macarounas, The Private Practice	
3:15-3:45pm	Afternoon Tea	

### **SESSION 3**

TIME	HAEMATOLOGY TRAINEES	TIME	MEDICAL ONCOLOGY TRAINEES
3:30-4:15pm	Bone Marrow Failure Syndromes Dr Lucy Fox, Peter McCallum Cancer Centre	3:45-4:25pm	Genetics for Oncologists A/Prof Yoland Antill, Cabrini Health
4:15-5:00pm	Update on treatment of Acute Lymphoblastic Leukaemia Dr Shaun Fleming, The Alfred Hospital	4:25-5:05pm	Psycho-oncology: Optimising psychosocial and supportive care A/Prof Joanne Shaw, The University of Sydney
5:00-7:00pm	'Clinicians, canapes and conversation' - Networking Event	- Ballroom Foyer	



## **SUNDAY 31ST JULY**

### **SESSION 1**

TIME	COMBINED SESSIONS
9:00-9:45am	Applying Geriatric Oncology to clinical practice Chair: Christopher Steer, PCPA President
9:45-10:30am	CNS malignancies in a nutshell Dr Elizabeth Ahern, Monash Health
10:30-10:50am	The future of Genomics Prof Ben Solomon, Peter McCallum Cancer Centre & Dr Hilda High, Sydney Cancer Genetics  Takeda  Takeda
10:50-11:20am	Morning tea

### **SESSION 2**

TIME	COMBINED SESSIONS	
11:20-12:05pm	PREMs and PROMs in Research and clinical practice Dr Kate Webber, Monash Health	
12:05-12:50pm	Communication – why it matters. A patient's perspective Dr Briony Scott, Principal of Wenona / Lung Cancer Advocate	
12:50-1:00pm	Q&A	
1:00pm	Lunch	
2:00pm	Close of Meeting	

## SPEAKER'S BIOGRAPHIES



### Professor H. Miles Prince AM

Professor Miles Prince AM is an Australian haematologist and Professor of Medicine at both Melbourne and Monash Universities. He is the Professor/Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and Haematologist at the Peter MacCallum Cancer Centre.

He is the recent Chairman of Medical Scientific Advisory Group to Myeloma Australia and Lead of the Australian T cell Lymphoma Network. He is on the Steering Committees of the international LymphomaHub and MultiplemyelomaHub.

He is a very active clinician, also overseeing clinical and laboratory research – the latter involving stem cell research and cancer immunology. He has been involved in numerous clinical trials of new therapies for blood cancers and has been the Principal Investigator of over 100 clinical trials involving myeloma, lymphoma, leukaemia, transplantation and supportive care.



### **Prof Hang Quach**

Professor Hang Quach is Director of Clinical Haematology Service and Director of Clinical Haematology Research at St Vincent's Hospital Melbourne.

She is also Professor of Haematology, Faculty of Medicine, Dentistry and Health Sciences at University of Melbourne.



#### **Prof Constantine Tam**

Prof Tam has a keen interest in the biology and treatment of CLL and low-grade lymphoproliferative diseases. Prof Tam has extensive experience in the conduct of clinical trials, particularly those involving targeted therapies in B-cell malignancies.

He is the global lead for the novel BTK inhibitor BGB-3111, and he completed the first study in the world to combine ibrutinib and venetoclax (published in New England Journal of Medicine in 2018).

Prof Tam participates actively in peer-review and is on the editorial board of Blood Advances and Leukemia & Lymphoma. Since 2012, he has received over \$14 million in grants. He has authored 149 papers, for a total of 3896 Web of Science™ citations. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Hematology Association.



### Dr Cameron McLaren, PCPA Board member

Dr McLaren is a medical oncologist from south-east Melbourne.

An early-adopter of VAD, he has conducted eligibility assessments in over 200 cases of application for VAD. He is a Clinical Moderator of the state-based VAD Community of Practice, an online forum for VAD-involved doctors to discuss their experiences, and is the founding director of VADANZ – Voluntary Assisted Dying practitioners of Australia and New Zealand; a group focused on the practice of, rather than the advocacy for, assisted dying and euthanasia services.



### **Hayley Tamborini**

As Executive General Manager of the Pharmaceutical Marketing team, Hayley is responsible for the product and portfolio strategy for the Arrotex prescription business.

With a career extending across the healthcare and pharmaceutical industries, Hayley is an experienced Pharmacist & Marketer with a passion for developing products, people, and programs that help pharmacies deliver excellence in patient care.

Hayley began her healthcare career as a Pharmacist after completing a Bachelor of Pharmacy from Sydney University. With over 17 years experience in study and industry, Hayley gained a deep and diverse understanding of the commercial imperatives that drive a pharmacy's success, holding roles at across Sales and Marketing functions.

## SPEAKER'S BIOGRAPHIES



### Kirsten Pilatti

Kirsten Pilatti is the CEO of Breast Cancer Network Australia (BCNA). She has an exceptional understanding of the cancer sector having spent over a decade at BCNA and five years at Cancer Council Victoria where she was responsible for delivering communications and campaigns around prevention messages. Highly regarded for her passion and focus on Australian women and men who have been affected by breast cancer, she is committed to giving everyone a voice and reducing the disparity of care across the country. She is also proud of the work she has done to turn the spotlight on important issues such as

access to breast reconstruction for women in Cairns and driving changes to the Australian healthcare system including access to drugs through the PBS such as the CDK inhibitors for Australians with metastatic breast cancer.



### Dr Benjamin Brady

Dr Benjamin Brady is a Medical Oncologist in the Skin and Melanoma Service at Peter Mac and also at Cabrini Health. He completed his Medical Oncology training at the Alfred, Royal Melbourne and Box Hill hospitals. Dr Brady spent many years in laboratory molecular biology at the Ludwig Institute for Cancer Research at the University of Melbourne and subsequently at the University of Colorado Health and Science Centre in Denver, CO, USA. Upon his return to Melbourne in 2002, he has been principal investigator and sub-investigator in many melanoma trials at Cabrini Health and Peter Mac. He has a

large melanoma practice in the south eastern suburbs of Melbourne through to far East Gippsland. He is presently Craft Group Leader in Cancer Services at Cabrini Health.



### Dr Richard De Boer

Dr. Richard de Boer completed his general medical training and then medical oncology training at the Royal Melbourne Hospital. In 1997 he undertook a 3-year breast and lung cancer clinical research Fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.

He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. He is currently a consultant medical oncologist in both the breast and lung cancer units at the Peter MacCallum Cancer Centre.

His primary breast cancer interests focus on endocrine therapy and mechanisms of resistance, and treatment-induced bone loss and bone metastases. His lung cancer interests focus on targeted therapies, predictors of response/survival, and small cell lung cancer. He is actively involved in clinical research, and is the principal investigator in both local and international studies.



# The Hon Ged Kearney MP Assistant Minister for Health and Aged Care

Ged Kearney is the Federal Member for Cooper. Ged has served in the parliament since March 2018, when she was elected in a by-election. She is the first woman to hold the seat.

Ged is the Assistant Minister for Health and Aged Care.

Ged started her working life as a nurse and rose to become Federal Secretary of the Australian Nursing Federation. From 2010, Ged served as the president of the ACTU – the peak body of Australia's union movement – where she fought for better conditions for Australian workers.

Ged's working life – from nurse to president of the ACTU to parliamentarian – has been about fighting for the rights of others.

She is a strong voice for social justice, workers' rights and universal healthcare inside Labor and the parliament. Ged is a passionate advocate for the environment and throughout her career she has supported a humane response to refugees.

Ged was born and raised in Melbourne and lived in Cooper for over 25 years. Ged has 4 children, 2 stepdaughters and 4 much-loved grandchildren.



### **Nick Chapman**

Nick Chapman is the Personalised Healthcare Lead at Roche Products Pty. He works across Roches' pharmaceutical and diagnostics division, leading a cross functional team that focuses on precision diagnostics, digital health and data-enabled health systems. Nick has almost 20 years pharmaceutical industry experience working in Australia, the UK, Switzerland and the US. The majority of his time has been spent in commercial and strategic partnerships functions. Nick has a BSc (Hons) from University of Manchester and an MBA from Warwick Business School.



### **Steven Macarounas**

Steven Macarounas began educating and advising healthcare professionals on business and financial management in 1987. He has dedicated almost 35 years of his working life to helping lift doctors level of knowledge on the crucial non-clinical aspects of their lives, such that they can make informed decisions, and smooth their path to success.

Steven holds a Bachelor of Commerce, a Diploma of Financial Planning and has developed and sold several medico-specialist financial services organisations in his career.

He is the founding partner of The Private Practice, Australia's premier business, financial and lifestyle educator of healthcare professionals – helping doctors address the value of their lives is his passion, providing the knowledge and tools to transform their lives is his calling.



### **Dr Lucy Fox**

Dr Lucy Fox is a haematologist with dual physician and pathology qualifications. She obtained her Medicine and Commerce / Science degrees at the University of Melbourne. She holds clinical appointments at Peter MacCallum Cancer Centre/Royal Melbourne Hospital and Austin Health. She is the Maddie Rielwoldt's Vision Bone Marrow Failure Research Fellow in the molecular haematology department of Peter MacCallum and is completing a doctoral degree in the inherited and acquired molecular changes in patients with bone marrow failure syndromes and inherited predisposition to haematological

malignancy. She is a clinical research fellow at the transfusion research unit at Monash University with a focus on the Aplastic Anaemia and other related bone marrow failure syndromes registry.



### Dr Shaun Fleming

Shaun is a clinical and laboratory haematologist at The Alfred Hospital in Melbourne Victoria where he leads the Acute Lymphoblastic Leukaemia program. He has a particular interest in the care of patients with acute leukaemia, cellular and immunotherapies including allogeneic stem cell transplantation and is the principal investigator on several clinical trials. He leads the ALLG ALLO8 study into older adults with Acute Lymphoblastic Leukaemia and in addition to his clinical trial research he has research interests in measurable residual disease and in the application of machine learning to prognostication in





### A/Prof Yoland Antill

Dr Yoland Antill is a Fellow of the Royal Australasian College of Physicians. She trained at Royal North Shore Hospital, in Sydney before completing a fellowship and doctoral studies at the Peter MacCallum Cancer Centre and now works full time across both private and public appointments at Cabrini Health, Royal Melbourne Hospital and Frankston Hospitals as a Medical Oncologist and Cancer Genetics specialist. Her working and research interests are in the management of Breast and Gynaecological cancers. She has more than 15 years' experience in both medical oncology and in the diagnosis and management

of hereditary cancer syndromes.

## **SPEAKER'S BIOGRAPHIES**



### A/Professor Joanne Shaw

A/Prof Joanne Shaw is the Psycho-oncology Co-operative Research Group (PoCoG) Executive Director and Senior Research Fellow in the School of Psychology, The University of Sydney. She is an experienced psycho-oncology, health communication and implementation science researcher. Her specific research interests include the development and evaluation of psychological and supportive care interventions to improve the outcomes for patients and families affected by cancer and supporting the health professionals who provide their care. A/Prof has a particular interest in developing alternative models

of care, quality and costs of evidence-based psycho-oncology interventions and health professional education. A/Prof Shaw co-authored the Australian clinical pathway for identification and management of anxiety and depression in adult cancer patients and her current research is focused on evidenced based strategies to facilitate implementation of the Clinical Pathway into routine cancer care.



### A/Prof Christopher Steer, PCPA Presiden

Christopher is a medical oncologist at Border Medical Oncology at the Albury Wodonga Regional Cancer Centre in regional NSW, Australia. He is an Associate Professor at the UNSW School of Clinical Medicine, Rural Clinical Campus in Albury and an Adjunct Professor at La Trobe University, Wodonga Campus.

Christopher is an investigator at the Border Medical Oncology Research Unit and strives to bring clinical trials to patients in regional Australia. Christopher is the co-chair of the Regional Trials network - Victoria (RTN-VIC) ReVITALISE Geriatric Oncology initiative. With \$2.7m of funding over 5 years the aim of this

project is to improve the access to clinical trials for older adults with cancer in regional Victoria and southern NSW. He also serves as the co-chair of the VCCC/MPCCC Research Advisory Committee for cancer in the Older Adult.

As the coordinator of Independent Learning Projects (ILPs) for the UNSW Albury Clinical Campus, Christopher works to foster research skills in local medical students and acts as a mentor for clinician investigators.



### Dr Elizabeth Ahern

Dr Elizabeth Ahern is a Medical Oncologist dedicated to improving outcomes for cancer patients through immune-oncology research. She has a strong interest in preclinical and translational relating to the interaction between immune system and cancer, and immunotherapies. Her clinical interests encompass early-phase trials, immunotherapy, brain cancer, head and neck cancer, and skin cancers including melanoma. Dr Ahern is an early career researcher. She submitted her PhD thesis in July 2020, titled "Targeting Receptor Activator of NF-kB pathways in combination immunotherapy" based on work

performed at Queensland Institute of Medical Research Berghofer, developing novel immunotherapy approaches for cancer in preclinical models. She is an investigator on four current translational grants to the value of >AUD\$3.5M, focusing on immuno-oncology in lung and colorectal cancer.



### **AProf Ben Solomon**

Professor Ben Solomon is a medical oncologist in the Lung Service and Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He has an interest in translational lung cancer research. Following a post-doctoral fellowship at the University of Colorado, Professor Solomon returned to Peter Mac in 2006, where he now practices as a medical oncologist with a research focus on clinical and translational research in lung cancer and head and neck cancer. His clinical trial work focuses on the identification of novel therapies for lung cancer and he has been involved in clinical trials

including trials with novel agents targeting ALK, EGFR, BRAF, cMET, RET, ROS1, NTRK and KRAS. He is a founding director of the Thoracic Oncology Group of Australia and serves on the board of the Cancer Council of Victoria.



### Dr Hilda High

Dr Hilda High is head of Sydney Cancer Genetics, the private practice she created in 2012. She sees patients throughout Australia via TeleHealth and in face-to face clinics at the SAN hospital, Wahroonga and in Ultimo, Sydney.

Dr Hilda High completed her medical degree at Sydney University with honours and was awarded The Dominque Clancey and Andrew Donald Memorial Prize: "in recognition of her dedication, selflessness and commitment to others". She is a registered Medical Oncologist specialising in Cancer Genetics and

completed her Master of Community Health, for which she won the Master of Community Health Prize, through the University of NSW.

Dr High is a key member of the Australian Government's Cancer Institute's eviQ group. Working with other experts, Hilda develops evidence-based, best-practice national guidelines for genetic testing and the management of inherited cancer syndromes.



### **Dr Kate Webber**

Dr Kate Webber is a medical oncologist with a keen interest in gynaecological oncology, cancer survivorship and clinical trials. Kate graduated from the University of New South Wales in 2002 with first class honours and completed her specialty training in medical oncology at St George and Prince of Wales Hospitals in Sydney. She was then appointed the inaugural Survivorship Research Fellow at the National Centre for Cancer Survivorship at the University of New South Wales where she completed a PhD examining long term health and psychosocial issues affecting cancer survivors whilst looking at novel

models of care for these patients.

Research arising from her PhD has been presented at scientific meetings for the American Society of Clinical Oncology, International Gynaecological Cancer Society and European Society of Gynaecological Oncology, in addition to Australian meetings.



### **Dr Briony Scott**

Dr Briony Scott is an Australian educator and columnist, and the principal at Wenona School in North Sydney. Dr Scott has a Masters and Doctorate in Education from the University of Sydney, specialising in girls' education; the utilisation of technology in the classroom; and non-government school funding policy. Prior to commencing at Wenona, Dr Scott was Principal of Roseville College, and served as Head of Senior School and Director of Studies at Oxford Falls Grammar School. She has also worked as a systems analyst for Italian computer firm Olivetti, and spent time volunteering with the Wheaton Rescue Squad in

Maryland, US. Dr Scott has been a regular columnist on educational and parenting issues for The North Shore Times and speaks frequently at community forums and conferences.

# Clinicians, canapes and conversation

Networking event Saturday 5-7pm at Ballroom Foyer













## THANK YOU TO OUR SPONSORS

**Platinum sponsor** 



**Gold Sponsors** 









**Sponsors & Partners** 



















#PCPA2022 #PCPAconf2022 #BeyondandTogether

www.pcpa.org.au